pyrazines has been researched along with cgc 11093 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Bush, D; Carew, JS; Casero, RA; Cleveland, JL; Goodwin, A; Houghton, JA; Marton, LJ; Nawrocki, ST; Reddy, VK; Rehg, JE | 1 |
1 other study(ies) available for pyrazines and cgc 11093
Article | Year |
---|---|
The novel polyamine analogue CGC-11093 enhances the antimyeloma activity of bortezomib.
Topics: Acetyltransferases; Animals; Antineoplastic Agents; Apoptosis; Boronic Acids; Bortezomib; Chromatography, High Pressure Liquid; Colony-Forming Units Assay; Drug Synergism; Drug Therapy, Combination; Humans; Immunoblotting; Immunoenzyme Techniques; In Situ Nick-End Labeling; JNK Mitogen-Activated Protein Kinases; Lung Neoplasms; Mice; Mice, SCID; Multiple Myeloma; Oxidoreductases Acting on CH-NH Group Donors; Polyamine Oxidase; Polyamines; Pyrazines; RNA, Small Interfering; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2008 |